HUTCHMED (China) (AIM:HCM) - 주가, 뉴스 및 분석

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

HCM 주식 개요

허치메드(중국) 유한회사는 자회사와 함께 홍콩 및 국제적으로 암 및 면역 질환에 대한 표적 치료제와 면역 요법을 발견, 개발 및 상업화합니다.

HCM 기본 분석
눈송이 점수
가치 평가	3/6
미래 성장	3/6
과거 실적	3/6
재무 상태	5/6
배당금	0/6

보상

공정 가치 추정치보다 낮은 59.4% 에서 거래

수익은 매년 18.65% 증가할 것으로 예상됩니다.

올해부터 흑자전환

위험 분석

위험 검사에서 HCM 에 대한 위험이 감지되지 않았습니다.

HUTCHMED (China) Limited 경쟁사

Hikma Pharmaceuticals

LSE:HIK

UK£4.2b

Animalcare Group

AIM:ANCR

UK£141.3m

GSK

LSE:GSK

UK£62.4b

AstraZeneca

LSE:AZN

UK£191.5b

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 HUTCHMED (China)
과거 주가
현재 주가	UK£2.76
52주 최고치	UK£3.53
52주 최저치	UK£1.85
베타	0.65
11개월 변경	-6.44%
3개월 변경 사항	2.99%
1년 변경 사항	48.87%
33년 변화	-47.92%
5년 변화	-21.81%
IPO 이후 변화	1,001.80%

최근 뉴스 및 업데이트

Recent updates

We Think HUTCHMED (China) (LON:HCM) Can Manage Its Debt With Ease

Apr 04

HUTCHMED (China) Limited's (LON:HCM) P/S Is Still On The Mark Following 31% Share Price Bounce

Mar 14

The HUTCHMED (China) Limited (LON:HCM) Analysts Have Been Trimming Their Sales Forecasts

Mar 01

With HUTCHMED (China) Limited (LON:HCM) It Looks Like You'll Get What You Pay For

Apr 19

주주 수익률

	HCM	GB Pharmaceuticals	GB 마켓
7D	-4.2%	-2.0%	-1.4%
1Y	48.9%	16.6%	6.4%

수익률 대 산업: HCM 지난 1년 동안 9.4 %를 반환한 UK Pharmaceuticals 산업을 초과했습니다.

수익률 대 시장: HCM 지난 1년 동안 6.1 %를 반환한 UK 시장을 초과했습니다.

가격 변동성

Is HCM's price volatile compared to industry and market?
HCM volatility
HCM Average Weekly Movement	5.9%
Pharmaceuticals Industry Average Movement	7.8%
Market Average Movement	4.7%
10% most volatile stocks in GB Market	10.9%
10% least volatile stocks in GB Market	2.6%

안정적인 주가: HCM 의 주가는 지난 3개월 동안 변동성이 심했습니다.

시간에 따른 변동성: HCM 의 주간 변동성( 6% )은 지난 1년 동안 안정적인 모습을 보였습니다.

회사 소개

설립	직원	CEO	웹사이트
2000	1,988	Wei-Guo Su	www.hutch-med.com

허치메드(중국) 유한회사는 자회사와 함께 홍콩 및 국제적으로 암 및 면역 질환에 대한 표적 치료제와 면역 요법을 발견, 개발 및 상업화합니다. 이 회사는 비소세포폐암(NSCLC), 유두상 신세포암(RCC), 위암(GC) 치료를 위한 사볼리티닙과 대장암(CRC), 유방암, 위암, 미세위성체 안정형-CRC 자궁내막암(EMC), NSCLC, RCC, 위장관, 자궁경부, 고형 종양 억제제인 프루퀸티닙을 개발합니다. 또한 췌장 신경내분비종양(NET), 비췌장 NET, 신경내분비암종, SCLC, 담도암, 고형암 치료에 사용되는 수루파티닙과 혈액암 및 특정 만성 면역 질환을 치료하는 소벨플레닙을 개발 중입니다.

HUTCHMED (China) Limited 기본 사항 요약

HUTCHMED (China) 의 수익과 매출은 시가총액과 어떻게 비교하나요?
HCM 기본 통계
시가총액	UK£2.36b
수익(TTM)	UK£79.72m
수익(TTM)	UK£662.92m

29.6x

P/E 비율

3.6x

P/S 비율

HCM 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
HCM 손익 계산서(TTM)
수익	US$838.00m
수익 비용	US$686.45m
총 이익	US$151.55m
기타 비용	US$50.77m
수익	US$100.78m

최근 보고된 수익

Dec 31, 2023

다음 수익 날짜

Jul 31, 2024

주당 순이익(EPS)	0.12
총 마진	18.08%
순이익 마진	12.03%
부채/자본 비율	10.7%

HCM 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

HCM 주식 개요

보상

위험 분석

HUTCHMED (China) Limited 경쟁사

LSE:HIK

UK£4.2b

AIM:ANCR

UK£141.3m

LSE:GSK

UK£62.4b

LSE:AZN

UK£191.5b

가격 내역 및 성능

최근 뉴스 및 업데이트

HUTCHMED (China) Limited to Report First Half, 2024 Results on Jul 31, 2024

Hutchmed Highlights Publication of Phase Iii Eslim-01 Results in the Lancet Haematology

HUTCHMED (China) Limited Initiates Phase I Trial of Menin Inhibitor HMPL-506 in Patients with Hematological Malignancies in China

HUTCHMED (China) Limited Highlights Publication of Phase III FRUTIGA Results in Nature Medicine

HUTCHMED (China) Limited Highlights Presentations of New and Updated Data from Several Studies of Compounds Discovered by HUTCHMED At the Upcoming American Society of Clinical Oncology

HUTCHMED (China) Limited Announces Executive Changes

Recent updates

HUTCHMED (China) Limited to Report First Half, 2024 Results on Jul 31, 2024

Hutchmed Highlights Publication of Phase Iii Eslim-01 Results in the Lancet Haematology

HUTCHMED (China) Limited Initiates Phase I Trial of Menin Inhibitor HMPL-506 in Patients with Hematological Malignancies in China

HUTCHMED (China) Limited Highlights Publication of Phase III FRUTIGA Results in Nature Medicine

HUTCHMED (China) Limited Highlights Presentations of New and Updated Data from Several Studies of Compounds Discovered by HUTCHMED At the Upcoming American Society of Clinical Oncology

HUTCHMED (China) Limited Announces Executive Changes

HUTCHMED (China) Limited Initiates the RAPMichael Registrational Phase III Trial of HMPL-306 for Patients with IDH1- and/or IDH2-Mutated Relapsed/Refractory Acute Myeloid Leukemia in China

HUTCHMED (China) Limited Initiates Phase II/III Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naive Pancreatic Ductal Adenocarcinoma in Collaboration with Hengrui

HUTCHMED (China) Limited Appoints Dr. Renu Bhatia as an Independent Non-Executive Director and a Member of Technical Committee, Effective May 13, 2024

HUTCHMED (China) Limited, Annual General Meeting, May 10, 2024

HUTCHMED (China) Limited Highlights Data to be Presented at AACR Congress 2024

We Think HUTCHMED (China) (LON:HCM) Can Manage Its Debt With Ease

HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status

HUTCHMED (China) Limited Announces Savolitinib sNDA Accepted in China for Treatment-Naive or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC

Hutchmed Initiates Registration Stage of the Eslim-02 Phase Ii/Iii Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China

HUTCHMED (China) Limited's (LON:HCM) P/S Is Still On The Mark Following 31% Share Price Bounce

Investor sentiment improves as stock rises 19%

The HUTCHMED (China) Limited (LON:HCM) Analysts Have Been Trimming Their Sales Forecasts

HUTCHMED (China) Limited Provides Revenue Guidance for the Year 2024

Full year 2023 earnings released: EPS: US$0.12 (vs US$0.43 loss in FY 2022)

Consensus revenue estimates decrease by 18%

Hutchmed (China) Limited Highlights Presentation of Phase III Data on Fruquintinib in Second-Line Gastric Cancer At Asco Plenary Series Session

HUTCHMED (China) Limited to Report Fiscal Year 2023 Results on Feb 28, 2024

HUTCHMED (China) Limited Receives Elunate® (Fruquintinib) Marketing Approval in Hong Kong for Treatment of Metastatic Colorectal Cancer

Consensus EPS estimates increase from loss to US$0.0102 profit

New minor risk - Share price stability

HUTCHMED (China) Limited Announces NDA Acceptance in China for Sovleplenib for the Treatment of Primary Immune Thrombocytopenia with Priority Review Status

Market Cool On HUTCHMED (China) Limited's (LON:HCM) Revenues

HUTCHMED (China) Limited Completes Enrollment of a Phase II/III Trial of Fruquintinib in Combination with Sintilimab for Advanced Renal Cell Carcinoma in China

Hutchmed (China) Limited Announces First in Human, Open-Label, Dose-Escalation Study of Erk1/2 Inhibitor Hmpl-295 in Patients with Advanced Solid Tumors

HUTCHMED (China) (LON:HCM) Is Using Debt Safely

Consensus EPS estimates increase from loss to US$0.0051 profit

HUTCHMED Announces that Takeda Receives U.S. FDA Approval of FRUZAQLA (fruquintinib) for Previously Treated Metastatic Colorectal Cancer

Consensus EPS estimates increase from loss to US$0.0016 profit

HUTCHMED (China) Limited Announces Submission of New Drug Application for Fruquintinib for Previously Treated Metastatic Colorectal Cancer in Japan

HUTCHMED (China) Limited Announces Presentation of Results from the Phase IIIb Trial of Savolitinib at the 2023 World Conference of Lung Cancer

Hutchmed (China) Limited Completes Patient Enrollment of a Bridging Study of Tazemetostat in Patients with Relapsed/Refractory Follicular Lymphoma in China

Consensus EPS estimates upgraded to US$0.0045 loss

New minor risk - Shareholder dilution

HUTCHMED Receives Breakthrough Therapy Designation in China for Savolitinib for Gastric Cancer

Does HUTCHMED (China) (LON:HCM) Have A Healthy Balance Sheet?

HUTCHMED (China) Limited Announces the Sovleplenib Phase III ESLIM-01 Study Met its Primary Endpoint in Primary Immune Thrombocytopenia in China

Key Executive exercised options to buy UK£6.7m worth of stock.

First half 2023 earnings released: EPS: US$0.20 (vs US$0.19 loss in 1H 2022)

HUTCHMED (China) Limited Receives Breakthrough Therapy Designation in China for Fruquintinib Combination with Sintilimab for Treatment of Advanced Endometrial Cancer, and Completes Enrollment of Registration Study

HUTCHMED (China) Limited Announces Changes to Board of Directors and Technical Committee

Hutchmed (China) Limited Initiates Phase I Study of Its Novel SHP2 Inhibitor HMPL-415 for Advanced Malignant Solid Tumors in China

Consensus estimates of losses per share improve by 42%

HUTCHMED (China) Limited to Report First Half, 2023 Results on Jul 31, 2023

HUTCHMED (China) Limited and Takeda Announce Publication of Phase III FRESCO-2 Results in the Lancet

Takeda and HUTCHMED Announce Marketing Authorization Application of Fruquintinib for Previously Treated Metastatic Colorectal Cancer Validated by the European Medicines Agency

Consensus EPS estimates upgraded to US$0.25 loss

HUTCHMED (China) Limited and Takeda Announce New Drug Application (NDA) for Fruquintinib for Treatment of Previously Treated Metastatic Colorectal Cancer Granted Priority Review

HUTCHMED (China) Limited Announces New and Updated Clinical Data Related to HUTCHMED

HUTCHMED (China) Limited Appoints Solange Peters as Independent Non-Executive Director, Member of the Technical Committee and Member of the Audit Committee

Is HUTCHMED (China) (LON:HCM) A Risky Investment?

With HUTCHMED (China) Limited (LON:HCM) It Looks Like You'll Get What You Pay For

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates fall by 24%, revenue upgraded